In this article (Mol Cancer Ther 2010;9:1489–502), which was published in the June 2010 issue of Molecular Cancer Therapeutics (1), the lapatinib IC50 values for two of the cell lines (MDA-MD-361 and HCC-202) have been incorrectly listed in Table 1. For these cell lines, cell doubling time was not correctly factored into the calculation of their IC50 values, which resulted in the cells being misclassified. The correct lapatinib IC50 values for these cell lines should be 0.292 ± 0.006 μmol/L for the MDA-MB-361 and 0.075 ± 0.026 μmol/L for the HCC-202 cell lines. Thus, these cell lines should not be categorized as “innately lapatinib resistant,” rather as “lapatinib sensitive.” These updated data have no significant effect on any of the statistical correlations listed in the article.

1.
O'Brien
NA
,
Browne
BC
,
Chow
L
,
Wang
Y
,
Ginther
C
,
Arboleda
J
, et al
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib
.
Mol Cancer Ther
2010
;
9
:
1489
502
.